NEW YORK, July 09, 2022 (WORLD NEWS CABLE) — Pomerantz LLP is investigating claims on behalf of investors of Apyx Medical Corporation (“Apyx” or the “Company”) apex. Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Apyx and any of its officers and/or directors have engaged in securities fraud or other illegal business practices.
Sponsored Content:
[Click here for information about joining the class action]
On March 14, 2022, Apyx disclosed that the United States Food and Drug Administration (“FDA”) would be destiny a Medical Device Safety Communication (“MDSC”) relating to the company’s advanced energy products. The Company also revealed that “[b]Based on our initial interactions with the FDA, we believe the agency’s MDSC will address the use of our Advanced Energy products outside of their FDA-approved indication for general use in soft tissue cutting, coagulation, and ablation during open surgical procedures and laparoscopic. .”
In this news, Apyx’s Values the price fell $4.02 per share, or 40.6%, to close at $5.88 per share on March 14, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading firms in the areas of antitrust, securities and corporate class action litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition it established, fighting for the rights of victims of securities fraud, breaches of fiduciary duty and corporate misconduct. The Firm has recovered numerous multi-million dollar damage awards on behalf of class members. Watch pomlaw.com.
Sponsored Content: OurLifeStore.com is a veteran-owned e-commerce with over 40,000 items at great prices and always free shipping
CONTACT:
Robert S Willoughby
Pomerantz LLP
[email protected]
888-476-6529 extension 7980